Share Price and Basic Stock Data
Last Updated: November 22, 2025, 11:02 am
| PEG Ratio | 1.13 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Choksi Laboratories Ltd operates in the medical research services industry, with a current market capitalization of ₹101 Cr and a share price of ₹145. The company has exhibited a consistent upward trend in revenue, with sales rising from ₹30.04 Cr in FY 2022 to ₹34.44 Cr in FY 2023, and further increasing to ₹41.78 Cr in FY 2025. The trailing twelve months (TTM) revenue stood at ₹44.14 Cr, indicating robust growth. Quarterly sales figures reflect this momentum, with the latest quarter (Mar 2025) recording sales of ₹11.40 Cr, a notable rise compared to ₹9.78 Cr in Mar 2023. This trend underscores the company’s ability to adapt to market demands and capitalize on opportunities within the medical research sector. Despite fluctuations in quarterly sales, the overall trajectory remains positive, suggesting a resilient business model supported by a diversified service portfolio.
Profitability and Efficiency Metrics
Choksi Laboratories reported a net profit of ₹1.66 Cr for FY 2025, with an earnings per share (EPS) of ₹2.19, reflecting a significant recovery from a net profit of only ₹0.21 Cr in FY 2022. The company’s operating profit margin (OPM) was recorded at 30.70%, showcasing strong operational efficiency compared to the industry average. The interest coverage ratio stood at 4.27x, indicating that the company is comfortably managing its interest obligations. However, the return on equity (ROE) of 6.63% and return on capital employed (ROCE) of 9.20% are relatively low, suggesting room for improvement in capital utilization. Choksi’s cash conversion cycle (CCC) of -474.95 days is notably high, indicating that the company efficiently converts its investments into cash, which is a positive sign for liquidity management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Choksi Laboratories is characterized by a lack of borrowings, reflecting a debt-free status. This is evidenced by the long-term debt to equity ratio of 0.64x and total debt to equity ratio of 1.19x, which are favorable compared to industry norms. The company’s book value per share has increased to ₹33.89 in FY 2025 from ₹25.70 in FY 2022, indicating a strengthening of shareholder equity. The current ratio of 0.68x and quick ratio of 0.66x suggest potential liquidity concerns; however, the absence of borrowings alleviates some financial stress. The price to book value (P/BV) ratio of 3.55x indicates that investors are willing to pay a premium for the stock, reflecting confidence in future growth potential. Overall, Choksi’s balance sheet is solid, but attention to liquidity ratios is necessary to ensure financial flexibility.
Shareholding Pattern and Investor Confidence
Choksi Laboratories’ shareholding structure reveals a significant public stake of 62.83%, while promoters hold 31.48% of the company. Foreign institutional investors (FIIs) have recently increased their stake from 0% to 5.69% over the reporting period, indicating growing investor confidence in the company. The number of shareholders has also risen, reaching 4,067 by Mar 2025, up from 3,518 in Dec 2022. This increasing interest from FIIs and the public reflects positively on Choksi’s market perception and future growth potential. However, the absence of domestic institutional investors (DIIs) may pose a risk in terms of stability and support for the stock price. The consistent promoter holding suggests confidence among management, which can be reassuring for retail investors.
Outlook, Risks, and Final Insight
Looking ahead, Choksi Laboratories is well-positioned for growth driven by its increasing revenue and strong operational metrics. However, the company faces risks related to its lower ROE and ROCE, which may hinder its ability to attract further investment. Additionally, the liquidity ratios suggest potential challenges in meeting short-term obligations, particularly if sales do not maintain their upward trend. The increasing FII participation could provide a buffer against volatility, but reliance on public investment without institutional support may expose the stock to greater fluctuations. Overall, Choksi’s strengths lie in its solid revenue growth and strong balance sheet, while risks include liquidity concerns and lower efficiency ratios. If these areas are addressed, Choksi Laboratories could emerge as a stronger player in the medical research services sector, enhancing shareholder value significantly.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Choksi Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 95.9 Cr. | 138 | 237/60.2 | 57.8 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,724 Cr. | 611 | 903/372 | 36.5 | 93.5 | 0.16 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,724.00 Cr | 374.50 | 47.15 | 64.35 | 0.08% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.14 | 8.24 | 8.68 | 7.84 | 9.78 | 8.88 | 7.95 | 8.79 | 11.12 | 10.74 | 9.26 | 10.38 | 11.40 |
| Expenses | 5.44 | 5.95 | 6.35 | 5.61 | 6.30 | 6.45 | 5.84 | 6.55 | 7.63 | 7.91 | 6.90 | 7.84 | 7.90 |
| Operating Profit | 4.70 | 2.29 | 2.33 | 2.23 | 3.48 | 2.43 | 2.11 | 2.24 | 3.49 | 2.83 | 2.36 | 2.54 | 3.50 |
| OPM % | 46.35% | 27.79% | 26.84% | 28.44% | 35.58% | 27.36% | 26.54% | 25.48% | 31.38% | 26.35% | 25.49% | 24.47% | 30.70% |
| Other Income | 0.02 | 0.00 | 0.02 | 0.10 | 2.26 | 0.00 | 0.05 | 0.00 | 0.06 | 0.01 | 0.01 | 0.01 | 0.04 |
| Interest | 0.76 | 0.75 | 0.87 | 0.93 | 0.94 | 0.82 | 0.74 | 0.67 | 0.77 | 0.72 | 0.66 | 0.69 | 0.58 |
| Depreciation | 1.35 | 1.40 | 1.31 | 1.36 | 1.42 | 1.39 | 1.41 | 1.43 | 1.49 | 1.50 | 1.61 | 1.68 | 1.70 |
| Profit before tax | 2.61 | 0.14 | 0.17 | 0.04 | 3.38 | 0.22 | 0.01 | 0.14 | 1.29 | 0.62 | 0.10 | 0.18 | 1.26 |
| Tax % | 14.18% | -107.14% | 64.71% | 425.00% | 11.54% | -59.09% | 0.00% | 57.14% | 46.51% | 30.65% | 20.00% | 44.44% | 26.98% |
| Net Profit | 2.24 | 0.30 | 0.06 | -0.13 | 2.99 | 0.36 | 0.01 | 0.06 | 0.68 | 0.42 | 0.08 | 0.11 | 0.92 |
| EPS in Rs | 3.22 | 0.43 | 0.09 | -0.19 | 4.29 | 0.52 | 0.01 | 0.09 | 0.98 | 0.60 | 0.11 | 0.16 | 1.32 |
Last Updated: July 16, 2025, 10:25 am
Below is a detailed analysis of the quarterly data for Choksi Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 11.40 Cr.. The value appears strong and on an upward trend. It has increased from 10.38 Cr. (Dec 2024) to 11.40 Cr., marking an increase of 1.02 Cr..
- For Expenses, as of Mar 2025, the value is 7.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.84 Cr. (Dec 2024) to 7.90 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Mar 2025, the value is 3.50 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Dec 2024) to 3.50 Cr., marking an increase of 0.96 Cr..
- For OPM %, as of Mar 2025, the value is 30.70%. The value appears strong and on an upward trend. It has increased from 24.47% (Dec 2024) to 30.70%, marking an increase of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Mar 2025, the value is 1.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.68 Cr. (Dec 2024) to 1.70 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 1.08 Cr..
- For Tax %, as of Mar 2025, the value is 26.98%. The value appears to be improving (decreasing) as expected. It has decreased from 44.44% (Dec 2024) to 26.98%, marking a decrease of 17.46%.
- For Net Profit, as of Mar 2025, the value is 0.92 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Dec 2024) to 0.92 Cr., marking an increase of 0.81 Cr..
- For EPS in Rs, as of Mar 2025, the value is 1.32. The value appears strong and on an upward trend. It has increased from 0.16 (Dec 2024) to 1.32, marking an increase of 1.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.16 | 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | 44.14 |
| Expenses | 17.85 | 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.48 | 32.27 |
| Operating Profit | 4.31 | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.30 | 11.87 |
| OPM % | 19.45% | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.89% |
| Other Income | 0.10 | 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | 0.06 |
| Interest | 1.19 | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.72 | 2.56 |
| Depreciation | 1.59 | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 | 6.75 |
| Profit before tax | 1.63 | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 | 2.62 |
| Tax % | 28.83% | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% | |
| Net Profit | 1.17 | 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.66 |
| EPS in Rs | 1.68 | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.38 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.79% | -18.18% | 23.61% | 51.69% | 18.52% | -342.50% | 32.73% | 108.05% | 1428.57% | -65.42% | 36.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | 6.60% | 41.79% | 28.07% | -33.17% | -361.02% | 375.23% | 75.31% | 1320.53% | -1493.99% | 102.36% |
Choksi Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 32% |
| 3 Years: | 93% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 83% |
| 3 Years: | 86% |
| 1 Year: | 175% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117.27 | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 |
| Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | |||
| Cash Conversion Cycle | 117.27 | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 |
| Working Capital Days | 8.73 | 29.26 | 3.34 | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 |
| ROCE % | 9.25% | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Diluted EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Cash EPS (Rs.) | 11.52 | 9.80 | 12.50 | 8.09 | 2.86 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Revenue From Operations / Share (Rs.) | 59.99 | 52.68 | 49.45 | 43.13 | 36.88 |
| PBDIT / Share (Rs.) | 16.23 | 14.90 | 15.01 | 12.93 | 6.62 |
| PBIT / Share (Rs.) | 6.89 | 6.70 | 7.12 | 5.13 | 0.01 |
| PBT / Share (Rs.) | 3.09 | 2.39 | 5.34 | 0.52 | -4.03 |
| Net Profit / Share (Rs.) | 2.19 | 1.59 | 4.61 | 0.29 | -3.74 |
| PBDIT Margin (%) | 27.04 | 28.29 | 30.35 | 29.97 | 17.95 |
| PBIT Margin (%) | 11.49 | 12.72 | 14.39 | 11.90 | 0.03 |
| PBT Margin (%) | 5.15 | 4.53 | 10.80 | 1.22 | -10.93 |
| Net Profit Margin (%) | 3.64 | 3.02 | 9.32 | 0.68 | -10.15 |
| Return on Networth / Equity (%) | 6.45 | 4.99 | 15.20 | 1.15 | -14.69 |
| Return on Capital Employeed (%) | 11.58 | 10.83 | 10.36 | 7.31 | 0.02 |
| Return On Assets (%) | 2.33 | 1.79 | 5.31 | 0.32 | -3.92 |
| Long Term Debt / Equity (X) | 0.64 | 0.81 | 1.12 | 1.54 | 1.77 |
| Total Debt / Equity (X) | 1.19 | 1.32 | 1.44 | 1.94 | 1.91 |
| Asset Turnover Ratio (%) | 0.65 | 0.59 | 0.55 | 0.45 | 0.39 |
| Current Ratio (X) | 0.68 | 0.77 | 1.11 | 0.90 | 0.80 |
| Quick Ratio (X) | 0.66 | 0.75 | 1.10 | 0.88 | 0.79 |
| Inventory Turnover Ratio (X) | 90.75 | 8.94 | 9.63 | 10.95 | 17.75 |
| Interest Coverage Ratio (X) | 4.27 | 3.45 | 2.99 | 2.81 | 1.64 |
| Interest Coverage Ratio (Post Tax) (X) | 1.57 | 1.37 | 1.27 | 1.06 | 0.07 |
| Enterprise Value (Cr.) | 111.15 | 58.14 | 53.31 | 52.04 | 39.01 |
| EV / Net Operating Revenue (X) | 2.66 | 1.58 | 1.55 | 1.73 | 1.52 |
| EV / EBITDA (X) | 9.84 | 5.60 | 5.10 | 5.78 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| Price / BV (X) | 3.55 | 1.33 | 1.10 | 0.98 | 0.30 |
| Price / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| EarningsYield | 0.01 | 0.03 | 0.13 | 0.01 | -0.47 |
After reviewing the key financial ratios for Choksi Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.52. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 11.52, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 59.99. It has increased from 52.68 (Mar 24) to 59.99, marking an increase of 7.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 16.23, marking an increase of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 6.89. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 6.89, marking an increase of 0.19.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.09. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 3.09, marking an increase of 0.70.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For PBDIT Margin (%), as of Mar 25, the value is 27.04. This value is within the healthy range. It has decreased from 28.29 (Mar 24) to 27.04, marking a decrease of 1.25.
- For PBIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has decreased from 12.72 (Mar 24) to 11.49, marking a decrease of 1.23.
- For PBT Margin (%), as of Mar 25, the value is 5.15. This value is below the healthy minimum of 10. It has increased from 4.53 (Mar 24) to 5.15, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has increased from 3.02 (Mar 24) to 3.64, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 15. It has increased from 4.99 (Mar 24) to 6.45, marking an increase of 1.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 11.58, marking an increase of 0.75.
- For Return On Assets (%), as of Mar 25, the value is 2.33. This value is below the healthy minimum of 5. It has increased from 1.79 (Mar 24) to 2.33, marking an increase of 0.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.64, marking a decrease of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has decreased from 1.32 (Mar 24) to 1.19, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.59 (Mar 24) to 0.65, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1.5. It has decreased from 0.77 (Mar 24) to 0.68, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.66, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 90.75. This value exceeds the healthy maximum of 8. It has increased from 8.94 (Mar 24) to 90.75, marking an increase of 81.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.27. This value is within the healthy range. It has increased from 3.45 (Mar 24) to 4.27, marking an increase of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.37 (Mar 24) to 1.57, marking an increase of 0.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111.15. It has increased from 58.14 (Mar 24) to 111.15, marking an increase of 53.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.66, marking an increase of 1.08.
- For EV / EBITDA (X), as of Mar 25, the value is 9.84. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.84, marking an increase of 4.24.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For Price / BV (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 3.55, marking an increase of 2.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Choksi Laboratories Ltd:
- Net Profit Margin: 3.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.58% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.45% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 57.8 (Industry average Stock P/E: 47.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Survey No 9/1, Near Tulsiyana Industrial Park, Indore Madhya Pradesh 453555 | compliance_officer@choksilab.com www.choksilab.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Choksi | Managing Director |
| Mrs. Stela Choksi | Whole Time Director |
| Ms. Himika Choksi | Whole Time Director |
| Mr. Vyangesh Choksi | Whole Time Director |
| Mr. Raghmendra Singh | Independent Director |
| Mrs. Meenaxi Patidar | Independent Director |
| Mrs. Prachi Mantri | Independent Director |
| Mrs. Abha Shastri | Independent Director |